Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Aardvark Therapeutics, Inc. (AARD) had Return on Tangible Equity of -54.01% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-57.59M |
|
-- |
|
-- |
|
$62.73M |
|
$-62.73M |
|
$5.13M |
|
$-57.59M |
|
$-57.59M |
|
$-57.59M |
|
$-57.59M |
|
$-57.59M |
|
$-57.59M |
|
$-62.73M |
|
$-63.99M |
|
19.62M |
|
19.62M |
|
$-2.93 |
|
$-2.93 |
|
| Balance Sheet Financials | |
$111.89M |
|
-- |
|
$5.29M |
|
$117.18M |
|
$10.55M |
|
-- |
|
-- |
|
$10.55M |
|
$106.63M |
|
$106.63M |
|
$106.63M |
|
21.82M |
|
| Cash Flow Statement Financials | |
$-54.17M |
|
$-49.67M |
|
$89.25M |
|
$61.64M |
|
$47.05M |
|
$-14.59M |
|
$3.95M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
10.61 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-54.27M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-54.01% |
|
|
Return on Tangible Equity |
-54.01% |
-49.15% |
|
-54.01% |
|
$4.89 |
|
$-2.77 |
|
$-2.76 |
|